A homozygous PRKN-associated juvenile Parkinson's disease with pregnancy in China

A homozygous PRKN-associated juvenile Parkinson's disease with pregnancy in China

BackgroundAlthough Parkinson's disease (PD) is the second most common neurodegenerative disorder, pregnancy in patients with PD is a relatively rare occurrence because the most common age of onset of PD is beyond the childbearing age, except in patients with Young-Onset PD (YOPD) caused by park...

Full description

Bibliographic Details
Main Authors:	Hong-xing Li, Mei Dong, Xiao-xiao Peng, Yi-zhe Liu, Han Wang, Chao Li, Yi-yi Du, Kai Zhang, Qiang Zong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Series:	Frontiers in Neurology
Subjects:	Parkinson's disease young-onset PD pregnancy PRKN gene levodopa/benserazide
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1103164/full

Similar Items

Effects of different levodopa doses on blood pressure in older patients with early and middle stages of Parkinson's disease
by: Dan Su, et al.
Published: (2023-07-01)

Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson’s disease: a disproportionality analysis of the FAERS database
by: Huaide Qiu, et al.
Published: (2025-03-01)

Systematic Functional Analysis of <i>PINK1</i> and <i>PRKN</i> Coding Variants
by: Benjamin J. Broadway, et al.
Published: (2022-08-01)

Experience in using levodopa-benserazide
by: Elena Anatolyevna Katunina, et al.
Published: (2015-10-01)

Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson’s disease
by: Yifan Yang, et al.
Published: (2023-10-01)

Investigation of <i>PRKN</i> Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
by: Ana Gabrielle Bispo, et al.
Published: (2023-08-01)

Structural and Functional Characterization of the Most Frequent Pathogenic PRKN Substitution p.R275W
by: Bernardo A. Bustillos, et al.
Published: (2024-09-01)

Promoting mitochondrial dynamics by inhibiting the PINK1–PRKN pathway to relieve diabetic nephropathy
by: Jun-yi Zhu, et al.
Published: (2024-04-01)

Comprehensive analysis of non-synonymous SNPs related to Parkinson’s disease and molecular dynamics simulation of PRKN mutants
by: Sapna Pandey, et al.
Published: (2023-01-01)

DYNLL1 ubiquitinated and degraded by E3 ligase PRKN regulates cell cycle arrest and apoptosis in lung adenocarcinoma cells
by: Hongjie Tang, et al.
Published: (2024-12-01)

MTFP1 is a mitophagy receptor that operates in PINK1/PRKN-dependent mitophagy and promotes oral cancer cell survival
by: Debasna P Panigrahi, et al.
Published: (2023-12-01)

HACD2 Promotes Pancreatic Cancer Progression by Enhancing PKM2 Dissociation From PRKN in a Dehydratase‐Independent Manner
by: Xuanning Chu, et al.
Published: (2025-03-01)

PRKN regulates inner mitochondrial membrane PHB2 during mitophagy
by: Shan Sun, et al.
Published: (2023-12-01)

Genetics of Parkinson´s disease: Recessive forms
by: P.A. Salles, et al.
Published: (2024-04-01)

Rare and novel variants of PRKN and PINK1 genes in Vietnamese patients with early‐onset Parkinson’s disease
by: Nguyen Dang Ton, et al.
Published: (2020-10-01)

Levodopa-carbidopa intestinal gel therapy in Parkinson’s disease: Procedure complications
by: Luminita Celia Popa, et al.
Published: (2020-06-01)

Reduced ER-mitochondrial contact sites and mitochondrial Ca2+ flux in PRKN-mutant patient tyrosine hydroxylase reporter iPSC lines
by: Mutsumi Yokota, et al.
Published: (2023-09-01)

Differential Amperometric Microneedle Biosensor for Wearable Levodopa Monitoring of Parkinson’s Disease
by: Lu Fang, et al.
Published: (2022-02-01)

Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia
by: O. S. Levin, et al.
Published: (2020-12-01)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
by: Aryun Kim, et al.
Published: (2018-05-01)

Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease
by: Xiaoqin He, et al.
Published: (2024-07-01)

Investigation of the Association of Homocysteine and MTHFR Polymorphisms and Treatment Options in Parkinson’s Disease in Central Anatolian Region*
by: Ramazan Emre, et al.
Published: (2015-12-01)

Rhabdomyolysis Related to Dyskinesia in Parkinson’s Disease
by: Hesna Bektaş, et al.
Published: (2014-04-01)

Malignant Syndrome in a Patient with Parkinson's Disease
by: Nesrin Helvacı Yılmaz, et al.
Published: (2012-09-01)

The risk of developing motor complications with Levodopa immediate versus dual release upon treatment initiation in Parkinson’s disease
by: Christian Ineichen, et al.
Published: (2023-01-01)

Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
by: K. Amande M. Pauls, et al.
Published: (2021-12-01)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
by: Kye Won Park, et al.
Published: (2020-09-01)

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
by: Nayron Medeiros Soares, et al.
Published: (2023-01-01)

Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease
by: Sebastiano Gangemi, et al.
Published: (2003-01-01)

Levodopa versus levodopa sparing in early parkinson’s disease: can we meet halfway?
by: Mayela Rodríguez-Violante, et al.
Published: (2024-07-01)

Mucuna beans administered through hydrogen-infused superheated steam in advanced Parkinson's disease
by: Ryuji Neshige, et al.
Published: (2024-01-01)

Interferência do tratamento medicamentoso imediato e tardio na doença de Parkinson no gerenciamento da disfagia
by: Paula Pinheiro Gerszt, et al.
Published: (2014-04-01)

Identification of electromyographic patterns of bradykinesia in patients with Parkinson's disease
by: Nikita Kozulin, et al.
Published: (2024-10-01)

Review of Mucuna pruriens L. therapeutic potential for Parkinson’s disease
by: A. S. Panova, et al.
Published: (2020-07-01)

Thrombocytopenia Associated with Levodopa Treatment
by: Ku-Eun Lee, et al.
Published: (2013-05-01)

Continuous long-range measurement of tonic dopamine with advanced FSCV for pharmacodynamic analysis of levodopa-induced dyskinesia in Parkinson’s disease
by: Jeongrak Park, et al.
Published: (2024-01-01)

Influência da levodopa sobre a fase oral da deglutição em pacientes com Doença de Parkinson Influence of levodopa on the oral phase of swallowing in patients with Parkinson's disease
by: Renata Mancopes, et al.
Published: (2013-01-01)

Retrospective Multicenter Study on Outcome Measurement for Dyskinesia Improvement in Parkinson’s Disease Patients with Pallidal and Subthalamic Nucleus Deep Brain Stimulation
by: Fangang Meng, et al.
Published: (2022-08-01)

Effect of DOPA decarboxylase inhibitor supplements on the incidence of urinary tract infections in Parkinson’s disease patients: A systematic review and meta-analysis of randomized controlled trials
by: Ismaeel AlShoaibi, et al.
Published: (2024-10-01)

Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson’s disease
by: Noriyuki Miyaue, et al.
Published: (2023-01-01)